Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 21, 2015

View Archived Issues

Genethon licenses CEVEC's lentivirus packaging cell line technology

Topica Pharmaceuticals to advance 10% luliconazole program into phase III development

Nestle Health Science licenses rights to Lipid Therapeutics' LT-02

Alector raises funds to advance immunomodulation approach for neurodegenerative diseases

Topline results from Apricus' phase IIa trial of RayVa for Reynaud's phenomenon

Arch Biopartners completes preclinical validation studies for AB-569

Infinity Pharmaceuticals adds IPI-549 to its pipeline for the treatment of solid tumors

FDA grants QIDP designation to Cempra's fusidic acid antibiotic

Shire's Intuniv approved in E.U. for ADHD

Novel MAb treats diabetes and fatty liver disease in obesity models

FDA accepts for review Heron's NDA resubmission for Sustol

FDA awards fast track designation to ZMapp for Ebola virus disease

Soluble Nogo-B improves angiogenesis in vitro

Cadila discloses BTK inhibitors

Takeda patents TBK1 inhibitors

Bristol-Myers Squibb presents MGAT2 inhibitors

Chinese researchers report discovery of compounds for psychiatric/neurological disorders

McGill University patent describes TC-PTP inhibitors

Pluristem and FDA agree development pathway for PLX-R18 in ARS

Beta-lactamase inhibitor CB-618 pharmacokinetics-pharmacodynamics characterized with other agents

Swissmedic approves Novartis's Entresto for heart failure

Clinigen and Neuraltus partner on managed access program for NP-001 in Europe

First clinical results disclosed for Enanta's EDP-239

New biomarkers described for liver transplant

Genmab and Novartis granted priority review for ofatumumab sBLA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.